バフェチニブ

バフェチニブ 価格

バフェチニブ 化学特性,用途語,生産方法

• 効能

  抗悪性腫瘍薬, チロシンキナーゼ阻害薬

• 説明

  Bcr-Abl, a fusion protein with deregulated tyrosine kinase activity, is highly expressed in chronic myelogenous leukemia (CML). Bafetinib is a rationally developed tyrosine kinase inhibitor based on the chemical structure of imatinib , with modifications added to improve binding and potency against Bcr-Abl kinase (IC₅₀ = 5.8 nM). It is 25- to 55-fold more potent than imatinib in vitro and ≥10-fold more potent in vivo. Bafetinib inhibits 12 out of the 13 most frequent imatinib-resistant Bcr-Abl point mutations, but not the T315I mutation and also targets the Src family kinase Lyn (IC₅₀ = 19 nM), which has been associated with resistance to imatinib in CML.

• 化学的特性

  Pale Yellow Solid

• 使用

  A substituted benzamide derivative structurally related to STI-571 (Imatinib Mesylate). It was identified as highly potent Bcr-Abl kinase inhibitor.

バフェチニブ 生産企業

Global(109)Suppliers

859212-16-1, バフェチニブ キーワード